Erfonrilimab
| Monoclonal antibody | |
|---|---|
| Type | F(ab')2 fragment |
| Target | CTLA-4, PD-L1 |
| Clinical data | |
| Drug class | Antineoplastic agent |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| UNII | |
Erfonrilimab is a investigational drug being evaluated for use in cancer immunotherapy.[1] It is a bispecific antibody targeting PD-L1 and CTLA-4.[2]
References[edit]
- ^ "Erfonrilimab - Alphamab". AdisInsight. Springer Nature Switzerland AG.
- ^ Xiong A, Li W, Li X, Fan Y, Ma Z, Fang J, et al. (September 2023). "Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study". European Journal of Cancer. 190: 112936. doi:10.1016/j.ejca.2023.05.024. PMID 37393762.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |